SE8205533L - PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES WITH THERAPEUTIC EFFECT - Google Patents

PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES WITH THERAPEUTIC EFFECT

Info

Publication number
SE8205533L
SE8205533L SE8205533A SE8205533A SE8205533L SE 8205533 L SE8205533 L SE 8205533L SE 8205533 A SE8205533 A SE 8205533A SE 8205533 A SE8205533 A SE 8205533A SE 8205533 L SE8205533 L SE 8205533L
Authority
SE
Sweden
Prior art keywords
group
denotes
formula
alk
alkyl
Prior art date
Application number
SE8205533A
Other languages
Swedish (sv)
Other versions
SE8205533D0 (en
SE454882B (en
Inventor
B J Price
J W Clitherow
J Bradshaw
Original Assignee
Allen & Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27448487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8205533(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB32465/76A external-priority patent/GB1565966A/en
Priority claimed from KR7701808A external-priority patent/KR810000355B1/en
Application filed by Allen & Hanburys Ltd filed Critical Allen & Hanburys Ltd
Publication of SE8205533D0 publication Critical patent/SE8205533D0/en
Publication of SE8205533L publication Critical patent/SE8205533L/en
Publication of SE454882B publication Critical patent/SE454882B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Abstract

Novel aminoalkylfuran derivatives of the general formula I: in which the symbols have the meaning indicated in Claim 1, are prepared by reaction of a compound of the formula with a compound of the formula R3NZZ'. A, B, Z and Z' have the meaning indicated in Claim 1. The aminoalkylfuran derivative can be used in the form of the free base or in the form of a physiologically acceptable salt or a hydrate. These novel aminoalkylfuran derivatives exhibit inhibition of gastric acid secretion if they are stimulated via histamine H2 receptors.

Claims (1)

PatentkravPatent claims 1. Firfarande fir framstallning as fbreningar med den formeln R2 N-A 1k0' (CH2)nX(CH2)mNHCNHR3 samt fysiologiskt godtagbara salter soh N-oxider och hydrat darav, dar symbolerna RI och g2, mom kan vara like eller alike, vardera betecknar en vateatom, en lagalkygrupp, en cykoalkylgrupp, en lAgalkenylgrupp, en aralky]grupp eller en lagalkylgrupp avbruten as en syreatom eller en grupp, dar 114betecknar , site eller lagalkyl, eller • A4 dar symbolerna Ri och R2 tillsammans med den kvaveatom, till silken de Ur bundna, bildar on heterocyklisk ring, vilken dessutom ken innehalla en syreatom eller en grupp -114-; dar 113 betecknar en vateatom, en lagal- Ry kylgrupp, en V',galkenylgrupp eller en alkoxialkylgrupp; (tar X betecknar 0112, 0 eller 8; dar Ytecknar =S, NR eller -CRR6; dar Alk be- teeknar en rak ellerrenad alkyle.la innehtillande 1-6 kolatomer; underkastas en Mannich-reaktion med en 1iimplig aldehyd och en sekundar amin eller ett salt as en primal, amin eller en sekundar amin till bild,ning as foreningar med formeln I, dar Y betecknar en =11I och Alk betecknar an metylengrupp eller enjargrenad alkylengrupp; eller alt (f) en farening med formein N17-Alk 410,3_ (C11)X(C112)NCI(IV) dar R1 R. •och n har de oven angivna betydelserna, omsatten , 2 Alk X, m med en amin med formeln 11311H2, clar R3 bar oVan anglers betydelse, till bildning as foreningar med fcrmeln I, dir Y betecknar svavel; varvid 1 samtliga fall slutprodukten eventuellt isoleras Sa50M ett fysiologiskt godtagbart salt eller omvandlas frdn ett dylikt salt till ett annat. allmanna (I) RI -oi- 1 7 dar R. betecknar en vgteatoM, en nitrogrupp, en cyangrupp, en lfigalkyi. grupp, en arylgrupp, en alkylsulfonylgrupp eller en arylsulfonylgrupp; dgr 26 betecknar en nitrogrupp, en arylsulfonylgrupp eller en alkylsulfonylgrupp; ddr m betecknar ett heltal frgn 2 till 4 och db.r n betecknar 1 eller 2, eller dal n betecknar 0,1 eller 2 ngr X betecknar 3 elier CE2; med den begrgnsningen att Y joke ban beteckna gruppen CHNO2 ngr R2, R2 och R3 betecknar metyl, Alk betecknar metylen, X betecknar S,nbetecknar 1 ochmbetecknar 2,1<11nnetec1A process for the preparation of compounds of the formula R2 NA 1k0 '(CH2) nX (CH2) mNHCNHR3 and physiologically acceptable salts such as N-oxides and hydrates thereof, wherein the symbols R1 and g2 may be the same or alike, each denoting a a water atom, a legal alkyl group, a cycloalkyl group, a 1Agalkenyl group, an aralkyl group or a lower alkyl group terminated as an oxygen atom or a group 114, denoting site or legal alkyl, or • A4 having the symbols R 1 and R 2 together with the nitrogen atom, to the silk de bonded, forms a heterocyclic ring, which in addition may contain an oxygen atom or a group -114-; wherein 113 represents a hydrogen atom, a legal alkyl group, a V ', galkenyl group or an alkoxyalkyl group; (takes X denotes 0112, 0 or 8; where Y denotes = S, NR or -CRR 6; where Alk denotes a straight or crude alkyl containing 1 to 6 carbon atoms; is subjected to a Mannich reaction with a simple aldehyde and a secondary amine or a salt as a primal, amine or a secondary amine to form compounds of formula I, wherein Y represents a = 11I and Alk represents a methylene group or a branched alkylene group, or alt (f) a compound of the formula N17-Alk 410 , 3_ (C11) X (C112) NCI (IV) dar R1 R. • and n have the meanings given above, turnover, 2 Alk X, m with an amine of the formula 11311H2, clar R3 bar oVan anglers meaning, to form compounds of formula I, dir Y represent sulfur, in which case the final product is optionally isolated from a physiologically acceptable salt or converted from such a salt to another. General (I) R 1 -oi- 1 7 dar R. denotes a vgteatoM, a nitro group, a cyano group, a oligalkyl group, an aryl group, an alkylsulfonyl group or an arylsul phonyl group; dgr 26 represents a nitro group, an arylsulfonyl group or an alkylsulfonyl group; ddr m denotes an integer from 2 to 4 and db.r n denotes 1 or 2, or dal n denotes 0.1 or 2 ngr X denotes 3 or CE2; with the proviso that Y joke ban denotes the group CHNO2 when R2, R2 and R3 denote methyl, Alk denotes methylene, X denotes S, n denotes 1 and denotes 2.1 <11nnetec1
SE8205533A 1976-08-04 1982-09-28 PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES WITH THERAPEUTIC EFFECT SE454882B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB32465/76A GB1565966A (en) 1976-08-04 1976-08-04 Aminoalkyl furan derivatives
GB5068576 1976-12-06
GB2018777 1977-05-13
KR7701808A KR810000355B1 (en) 1977-05-13 1977-08-04 Preparation for pharmacologically active compounds

Publications (3)

Publication Number Publication Date
SE8205533D0 SE8205533D0 (en) 1982-09-28
SE8205533L true SE8205533L (en) 1982-09-28
SE454882B SE454882B (en) 1988-06-06

Family

ID=27448487

Family Applications (3)

Application Number Title Priority Date Filing Date
SE7708521A SE437373B (en) 1976-08-04 1977-07-25 PROCEDURE FOR PREPARING AN AMINOAL COOLING RANGE DERIVATIVE WITH THERAPEUTIC EFFECT
SE8205533A SE454882B (en) 1976-08-04 1982-09-28 PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES WITH THERAPEUTIC EFFECT
SE8206556A SE454883B (en) 1976-08-04 1982-11-17 AMINOALKYL REFERENCE DERIVATIVES FOR USING INTERMEDIATES IN THE PREPARATION OF AMINOALKYL REFERENCE DERIVATIVES WITH THERAPEUTIC EFFECT

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SE7708521A SE437373B (en) 1976-08-04 1977-07-25 PROCEDURE FOR PREPARING AN AMINOAL COOLING RANGE DERIVATIVE WITH THERAPEUTIC EFFECT

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE8206556A SE454883B (en) 1976-08-04 1982-11-17 AMINOALKYL REFERENCE DERIVATIVES FOR USING INTERMEDIATES IN THE PREPARATION OF AMINOALKYL REFERENCE DERIVATIVES WITH THERAPEUTIC EFFECT

Country Status (16)

Country Link
AT (1) AT375931B (en)
CH (2) CH642072A5 (en)
CY (1) CY1077A (en)
DE (2) DE2760097C2 (en)
DK (2) DK148258C (en)
ES (2) ES461334A1 (en)
FI (1) FI72318C (en)
HK (1) HK55780A (en)
IE (1) IE45456B1 (en)
IT (2) IT1126759B (en)
KE (1) KE3080A (en)
NZ (2) NZ191383A (en)
PH (1) PH13540A (en)
PT (1) PT66874B (en)
SE (3) SE437373B (en)
YU (2) YU40006B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203909A (en) * 1978-09-26 1980-05-20 Bristol-Myers Company Furan compounds
YU52598A (en) * 1998-11-19 2001-05-28 D.D. Zdravlje- sektor za istraživanje i razvoj Procedure for synthesis of n-[2[[[5-[ (dialkylamino)methyl] -2-furanil]methyl]thi0]etyl]-n'-alkyl-2-nitro 1,1 alkendiamine and its hydrochloride

Also Published As

Publication number Publication date
DK416384D0 (en) 1984-08-30
SE437373B (en) 1985-02-25
SE454883B (en) 1988-06-06
DK337977A (en) 1978-02-05
NZ184759A (en) 1980-09-12
IE45456L (en) 1978-02-04
SE8205533D0 (en) 1982-09-28
DK149952C (en) 1987-07-06
PT66874A (en) 1977-09-01
HK55780A (en) 1980-10-10
YU200082A (en) 1983-01-21
FI772264A (en) 1978-02-05
DK149952B (en) 1986-11-03
FI72318C (en) 1987-05-11
CY1077A (en) 1980-12-27
IT1126759B (en) 1986-05-21
IT8548437A0 (en) 1985-08-01
DE2760097C2 (en) 1989-08-17
ES470836A1 (en) 1979-02-16
NZ191383A (en) 1980-09-12
DE2759959C2 (en) 1988-08-04
DK416384A (en) 1984-08-30
SE8206556L (en) 1982-11-17
YU40088B (en) 1985-06-30
SE454882B (en) 1988-06-06
YU191177A (en) 1983-01-21
YU40006B (en) 1985-06-30
IT1221058B (en) 1990-06-21
DK148258C (en) 1985-10-14
CH641176A5 (en) 1984-02-15
FI72318B (en) 1987-01-30
PH13540A (en) 1980-06-26
SE7708521L (en) 1978-02-05
SE8206556D0 (en) 1982-11-17
CH642072A5 (en) 1984-03-30
ATA574077A (en) 1984-02-15
KE3080A (en) 1980-10-03
DK148258B (en) 1985-05-20
ES461334A1 (en) 1979-05-16
IE45456B1 (en) 1982-08-25
PT66874B (en) 1979-01-23
AT375931B (en) 1984-09-25

Similar Documents

Publication Publication Date Title
US3763156A (en) 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
AU594739B2 (en) Thieno-1,4-diazepines
AU2001272476A1 (en) Piperidines for use as orexin receptor antagonists
IE791945L (en) Indoles.
IE41539L (en) Chroman derivatives.
KR830009773A (en) Method for preparing 1,2-diamino cyclobutene-3,4-dione
KR840004107A (en) Preparation of 1,4-dihydropyridine-3,5-dicarboxylic acid ester derivative
AU6747687A (en) New derivatives of decahydroquinoline,their preparation process, the preparation intermediates, their use as medicaments and the compositions containing them
HUT41713A (en) Process for production of //arol-cyclobutyl/ alkyl/-amins and medical preparatives containing thereof
KR830000694A (en) Method for producing heterocycle derivatives
ES8207151A1 (en) New imidazolylphenyl amidines, processes for their preparation and their pharmaceutical use, and intermediates of preparation.
EP0000220A1 (en) Dihydrouracils, process for their preparation and pharmaceuticals containing them
AU644295B2 (en) 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics
AU554976B2 (en) 1-phenyl-2-aminocarbonylindole compounds
SE8205533L (en) PROCEDURE FOR THE PREPARATION OF AMINOAL COOLING RANGE DERIVATIVES WITH THERAPEUTIC EFFECT
IE782028L (en) Substituted furans
KR880001988B1 (en) Process for preparing heterocyclic compounds
ES486071A1 (en) Amine derivatives
US3396165A (en) 9-aminomethyl-3, 8-diloweralkyl-10-hydroxy-5-oxo-1, 2, 3, 4-tetrahydrobenzopyrano [3,4-c] pyridines
KR860002507A (en) Method for preparing Substituted 7-Oxomitosan
DE3164667D1 (en) Amino-alcoxy pyrazoles, process for their preparation and medicaments containing them
DE3689762T2 (en) Antibacterial compounds, their production and use.
NO844778L (en) PROCEDURE FOR PREPARING 2-HYDROXY-PROPIOPHENOMIC DERIVATIVES
IE801382L (en) Piperidines.
ES8207500A1 (en) Biologically-active tricyclic amines, methods for their preparation and pharmaceutical compositions containing same.

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8205533-6

Effective date: 19930204

Format of ref document f/p: F